What changed: Oesophageal cancer
Every dated change on the records linked to Oesophageal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
August 2026 · 1
2026 · 6
- 2026Trial resultBL-B01D1-307BL-B01D1-307 reported
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
- 2026Trial resultCLARITY-Gastric 01CLARITY-Gastric 01 reported
Co-primary endpoints including OS met (July 2026); numbers pending.
- 2026Trial resultHERIZON-GEA-01HERIZON-GEA-01 reported
PFS 12.
- 2026Trial resultPANKU-Esophagus01 (BL-B01D1-305)PANKU-Esophagus01 (BL-B01D1-305) reported
OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation.
- 2026MilestoneBL-B01D1-307Iza-bren phase 3 positive
A milestone in how this cancer is treated.
- 2026MilestonePANKU-Esophagus01 (BL-B01D1-305)PANKU-Esophagus01: iza-bren improves OS in second-line ESCC; HERIZON-GEA-01 for HER2+ GEJ; CheckMate 648 five-year data
A milestone in how this cancer is treated.
December 2025 · 1
2025 · 2
2024 · 1
2023 · 3
- 2023ApprovalSintilimabSintilimab approved in China
First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)
- 2023Trial resultSANOSANO reported
2-year OS non-inferior (HR 1.
- 2023MilestoneSANOSANO: active surveillance non-inferior after complete response
A milestone in how this cancer is treated.
2022 · 5
- 2022ApprovalSintilimabSintilimab approved in China
First-line oesophageal squamous cell carcinoma with chemotherapy (ORIENT-15)
- 2022Trial resultJUPITER-06JUPITER-06 reported
OS 17.
- 2022Trial resultRATIONALE-302RATIONALE-302 reported
OS 8.
- 2022Trial resultRATIONALE-306RATIONALE-306 reported
OS 17.
- 2022MilestoneCheckMate 648CheckMate 648: nivolumab + chemotherapy and nivolumab + ipilimumab approved; RATIONALE-306 reported
A milestone in how this cancer is treated.
2021 · 5
- 2021Trial resultCheckMate 577CheckMate 577 reported
DFS 22.
- 2021Trial resultCheckMate 648CheckMate 648 reported
PD-L1 ≥1%: OS 15.
- 2021Trial resultESCORT-1stESCORT-1st reported
OS 15.
- 2021MilestoneOesophageal cancerCheckpoint inhibitors first line
A milestone in how this cancer is treated.
- 2021MilestoneCROSSCROSS 10-year data; CheckMate 577 adjuvant nivolumab; KEYNOTE-590 and ESCORT-1st first-line chemo-IO
A milestone in how this cancer is treated.
2020 · 2
2019 · 2
- 2019ApprovalPD-L1 IHC 22C3 pharmDxPD-L1 IHC 22C3 pharmDx approved in US
Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)
- 2019MilestonePembrolizumabPD-1 blockade second line: pembrolizumab (KEYNOTE-181) and nivolumab (ATTRACTION-3)
A milestone in how this cancer is treated.
2012 · 4
- 2012Trial resultCROSSCROSS reported
10-year OS 38% vs 25%; median OS 49.
- 2012Trial resultCROSSCROSS reported
Median overall survival 49.
- 2012MilestoneOesophageal cancerCROSS: neoadjuvant chemoradiation
A milestone in how this cancer is treated.
- 2012MilestoneCROSSCROSS: neoadjuvant chemoradiation becomes standard
A milestone in how this cancer is treated.